We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

SGSN:SIXSGS SA Analysis

Data as of 2026-03-11 - not real-time

CHF 92.38

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

SGS SA (SGSN.SW) is trading at CHF 92.38, just above the near‑term support of CHF 90.20 and below both the 20‑day and 50‑day SMAs (≈CHF 94), indicating a modest cushion but still under pressure from a bearish MACD histogram. Volume is increasing and the 30‑day volatility is high at ~23.5%, suggesting active price swings while the low beta (~0.30) tempers market‑wide risk. The stock’s PE of 26.7 is slightly below the industry average of 29.4, yet the price‑to‑book ratio of 19.8 is extremely elevated, and the DCF fair value of CHF 49.6 is far below the current price, hinting at limited upside beyond the modest 6.6% upside estimate.
Fundamentally, SGS delivers a solid dividend yield of 3.49% with a high payout ratio (~92%), but its balance sheet is heavily leveraged (debt‑to‑equity > 490) and cash reserves cover less than half of total debt. Operating margins are healthy (≈15%) and ROE is exceptionally high, but the combination of high leverage and near‑full dividend payout raises questions about long‑term dividend sustainability. The company benefits from a diversified global footprint and a stable regulatory environment for testing and certification services, supporting a “blend” growth‑value profile despite the current valuation pressures.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price hovering just above key support level
  • Bearish MACD divergence despite bullish trend label
  • Increasing trading volume indicating short‑term interest

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Potential upside toward resistance around CHF 97.5
  • Attractive dividend yield relative to peers
  • Forward PE improvement to ~20x supporting valuation

Long Term

> 3 years
Neutral
Model confidence: 6/10

Key Factors

  • High leverage and near‑full dividend payout risk
  • Strong brand and global diversification in a regulated industry
  • Elevated price‑to‑book ratio limiting long‑term upside

Key Metrics & Analysis

Financial Health

Revenue Growth1.90%
Profit Margin9.62%
P/E Ratio26.7
ROE76.60%
ROA8.41%
Debt/Equity492.16
P/B Ratio19.8
Op. Cash FlowCHF1.2B
Free Cash FlowCHF805.5M
Industry P/E29.4

Technical Analysis

TrendBullish
RSI43.7
SupportCHF 90.20
ResistanceCHF 97.48
MA 20CHF 94.03
MA 50CHF 94.03
MA 200CHF 87.61
MACDBearish
VolumeIncreasing
Fear & Greed Index76.91

Valuation

Fair ValueCHF 49.64
Target PriceCHF 98.47
Upside/Downside6.59%
GradeFair
TypeBlend
Dividend Yield3.49%

Risk Assessment

Beta0.30
Volatility23.49%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.